| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 8 | 2022 | 62 | 2.590 |
Why?
|
| Brain Neoplasms | 8 | 2022 | 308 | 1.940 |
Why?
|
| Radiation Oncology | 8 | 2021 | 51 | 1.780 |
Why?
|
| Prostatic Neoplasms | 14 | 2024 | 416 | 1.780 |
Why?
|
| Hyperbaric Oxygenation | 2 | 2022 | 16 | 1.310 |
Why?
|
| Radiation Injuries | 3 | 2022 | 66 | 1.220 |
Why?
|
| Androgen Antagonists | 7 | 2024 | 25 | 0.950 |
Why?
|
| Neoplasms | 8 | 2020 | 1361 | 0.930 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2016 | 35 | 0.920 |
Why?
|
| Adaptive Clinical Trials as Topic | 2 | 2020 | 5 | 0.820 |
Why?
|
| Research Design | 4 | 2021 | 573 | 0.810 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 4 | 2017 | 58 | 0.800 |
Why?
|
| Tumor Burden | 2 | 2012 | 68 | 0.760 |
Why?
|
| Radiotherapy | 3 | 2017 | 64 | 0.750 |
Why?
|
| Chemoradiotherapy | 3 | 2018 | 66 | 0.750 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2020 | 8 | 0.670 |
Why?
|
| Proton Therapy | 1 | 2020 | 8 | 0.660 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2024 | 14 | 0.580 |
Why?
|
| Biological Products | 1 | 2020 | 94 | 0.580 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 419 | 0.520 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2016 | 38 | 0.510 |
Why?
|
| Cisplatin | 1 | 2016 | 139 | 0.500 |
Why?
|
| Humans | 54 | 2024 | 63299 | 0.490 |
Why?
|
| Communication | 1 | 2020 | 571 | 0.480 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2016 | 257 | 0.460 |
Why?
|
| Brachytherapy | 3 | 2021 | 37 | 0.440 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 105 | 0.380 |
Why?
|
| Societies, Medical | 5 | 2017 | 375 | 0.370 |
Why?
|
| Prostheses and Implants | 2 | 2011 | 71 | 0.360 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 345 | 0.350 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 71 | 0.340 |
Why?
|
| Adenocarcinoma | 4 | 2018 | 342 | 0.340 |
Why?
|
| Radiotherapy, Conformal | 2 | 2010 | 19 | 0.320 |
Why?
|
| Medical Errors | 1 | 2011 | 196 | 0.310 |
Why?
|
| Time Factors | 8 | 2024 | 3762 | 0.300 |
Why?
|
| Gold | 1 | 2011 | 226 | 0.300 |
Why?
|
| Radiation Protection | 1 | 2009 | 26 | 0.300 |
Why?
|
| Cranial Irradiation | 2 | 2022 | 11 | 0.290 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2021 | 26 | 0.290 |
Why?
|
| Male | 26 | 2024 | 29823 | 0.290 |
Why?
|
| Quality Assurance, Health Care | 2 | 2017 | 255 | 0.290 |
Why?
|
| Mastectomy, Segmental | 2 | 2021 | 46 | 0.290 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 447 | 0.280 |
Why?
|
| Treatment Outcome | 12 | 2022 | 5655 | 0.270 |
Why?
|
| Aged | 16 | 2024 | 14396 | 0.260 |
Why?
|
| Patient Selection | 3 | 2017 | 488 | 0.250 |
Why?
|
| Electron Spin Resonance Spectroscopy | 3 | 2014 | 26 | 0.250 |
Why?
|
| Prostate-Specific Antigen | 6 | 2023 | 76 | 0.250 |
Why?
|
| Neoplasm Grading | 6 | 2024 | 92 | 0.240 |
Why?
|
| Middle Aged | 17 | 2024 | 17556 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2024 | 769 | 0.240 |
Why?
|
| Oxygen | 3 | 2022 | 315 | 0.240 |
Why?
|
| Pharmacokinetics | 1 | 2005 | 6 | 0.230 |
Why?
|
| Breast Neoplasms | 3 | 2021 | 1195 | 0.230 |
Why?
|
| Nonlinear Dynamics | 1 | 2005 | 25 | 0.230 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 297 | 0.220 |
Why?
|
| Follow-Up Studies | 7 | 2024 | 2457 | 0.220 |
Why?
|
| Computer Simulation | 3 | 2020 | 477 | 0.220 |
Why?
|
| Cystectomy | 1 | 2024 | 35 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 734 | 0.220 |
Why?
|
| Glioblastoma | 2 | 2018 | 157 | 0.220 |
Why?
|
| Models, Statistical | 3 | 2020 | 308 | 0.210 |
Why?
|
| Sample Size | 2 | 2020 | 65 | 0.200 |
Why?
|
| Radiopharmaceuticals | 2 | 2016 | 185 | 0.200 |
Why?
|
| Radiotherapy Dosage | 4 | 2017 | 84 | 0.200 |
Why?
|
| Quality of Life | 2 | 2022 | 1225 | 0.200 |
Why?
|
| Female | 17 | 2024 | 32793 | 0.200 |
Why?
|
| Adult | 14 | 2024 | 16788 | 0.190 |
Why?
|
| Survival Analysis | 4 | 2019 | 581 | 0.190 |
Why?
|
| Oximetry | 2 | 2014 | 48 | 0.190 |
Why?
|
| Medical Records | 2 | 2020 | 137 | 0.180 |
Why?
|
| Nuclear Medicine | 1 | 2021 | 4 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 178 | 0.180 |
Why?
|
| Arteriovenous Malformations | 1 | 2001 | 43 | 0.170 |
Why?
|
| Combined Modality Therapy | 5 | 2024 | 372 | 0.170 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2001 | 39 | 0.170 |
Why?
|
| United States | 8 | 2021 | 7826 | 0.170 |
Why?
|
| Fibrosarcoma | 1 | 2000 | 13 | 0.170 |
Why?
|
| Central Nervous System Diseases | 1 | 2001 | 57 | 0.170 |
Why?
|
| Retrospective Studies | 3 | 2022 | 6635 | 0.160 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 1996 | 52 | 0.160 |
Why?
|
| Ocular Physiological Phenomena | 1 | 2019 | 2 | 0.160 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 298 | 0.160 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2019 | 51 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 1 | 2000 | 139 | 0.160 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 455 | 0.150 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 5452 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 860 | 0.150 |
Why?
|
| Goserelin | 1 | 2018 | 2 | 0.150 |
Why?
|
| Flutamide | 1 | 2018 | 4 | 0.150 |
Why?
|
| Leuprolide | 1 | 2018 | 16 | 0.150 |
Why?
|
| Light | 1 | 2019 | 202 | 0.150 |
Why?
|
| Neoplasm Staging | 4 | 2024 | 501 | 0.150 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2012 | 77 | 0.140 |
Why?
|
| Carmustine | 1 | 2018 | 11 | 0.140 |
Why?
|
| Young Adult | 5 | 2018 | 4686 | 0.140 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2018 | 34 | 0.140 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 12 | 0.140 |
Why?
|
| Salvage Therapy | 2 | 2012 | 75 | 0.140 |
Why?
|
| Oligodendroglioma | 1 | 2017 | 7 | 0.140 |
Why?
|
| Glioma | 1 | 2018 | 98 | 0.130 |
Why?
|
| Medical Oncology | 1 | 2017 | 66 | 0.130 |
Why?
|
| Karnofsky Performance Status | 1 | 2016 | 12 | 0.130 |
Why?
|
| Rectal Diseases | 1 | 1996 | 28 | 0.130 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 834 | 0.130 |
Why?
|
| Analysis of Variance | 2 | 2012 | 608 | 0.130 |
Why?
|
| Rectum | 1 | 1996 | 89 | 0.120 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1996 | 78 | 0.120 |
Why?
|
| Prognosis | 5 | 2024 | 1747 | 0.120 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2015 | 19 | 0.120 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2015 | 12 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 506 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 35 | 0.120 |
Why?
|
| Postoperative Period | 2 | 2012 | 138 | 0.110 |
Why?
|
| Genetic Variation | 1 | 2017 | 383 | 0.110 |
Why?
|
| Watchful Waiting | 1 | 2015 | 29 | 0.110 |
Why?
|
| ErbB Receptors | 1 | 2015 | 114 | 0.110 |
Why?
|
| Patient Safety | 1 | 2017 | 243 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2016 | 568 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 2 | 1994 | 453 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 187 | 0.110 |
Why?
|
| Canada | 3 | 2021 | 154 | 0.110 |
Why?
|
| Radiometry | 1 | 2014 | 36 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 166 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2024 | 44 | 0.100 |
Why?
|
| Thalidomide | 1 | 2012 | 34 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 411 | 0.100 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2012 | 6 | 0.090 |
Why?
|
| Sulfones | 1 | 2012 | 39 | 0.090 |
Why?
|
| Erectile Dysfunction | 1 | 2012 | 24 | 0.090 |
Why?
|
| Spouses | 1 | 2012 | 40 | 0.090 |
Why?
|
| Piperazines | 1 | 2012 | 81 | 0.090 |
Why?
|
| Disease Progression | 2 | 2015 | 1164 | 0.090 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2011 | 9 | 0.090 |
Why?
|
| Hormones | 1 | 2011 | 60 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 2021 | 122 | 0.080 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2010 | 15 | 0.080 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2010 | 1 | 0.080 |
Why?
|
| Technology, Radiologic | 1 | 2010 | 9 | 0.080 |
Why?
|
| Amides | 1 | 2010 | 55 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 663 | 0.080 |
Why?
|
| Meningioma | 2 | 2019 | 60 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 341 | 0.080 |
Why?
|
| Carbon | 1 | 2010 | 51 | 0.080 |
Why?
|
| Pyridines | 1 | 2010 | 111 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2024 | 2076 | 0.080 |
Why?
|
| Area Under Curve | 2 | 2010 | 146 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2022 | 3283 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 668 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2021 | 59 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2024 | 729 | 0.070 |
Why?
|
| Melanoma | 1 | 2011 | 331 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 2 | 2020 | 194 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 2164 | 0.060 |
Why?
|
| Safety | 2 | 2018 | 145 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2013 | 863 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2005 | 35 | 0.060 |
Why?
|
| Connective Tissue | 1 | 2004 | 12 | 0.060 |
Why?
|
| Clinical Medicine | 1 | 2004 | 16 | 0.060 |
Why?
|
| BCG Vaccine | 1 | 2024 | 51 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 242 | 0.050 |
Why?
|
| Radiation Tolerance | 2 | 1994 | 52 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2015 | 88 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 421 | 0.050 |
Why?
|
| Rectal Neoplasms | 1 | 2004 | 104 | 0.050 |
Why?
|
| Survival Rate | 2 | 2012 | 850 | 0.050 |
Why?
|
| Mutation | 3 | 2017 | 2607 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2022 | 278 | 0.050 |
Why?
|
| Muscles | 1 | 2022 | 179 | 0.050 |
Why?
|
| Adolescent | 3 | 2018 | 6241 | 0.050 |
Why?
|
| Androgens | 1 | 2021 | 48 | 0.040 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 7 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 89 | 0.040 |
Why?
|
| Biopsy | 1 | 2022 | 444 | 0.040 |
Why?
|
| Neuroma, Acoustic | 1 | 2001 | 13 | 0.040 |
Why?
|
| Biomarkers | 2 | 2022 | 1397 | 0.040 |
Why?
|
| Quality Control | 2 | 2011 | 74 | 0.040 |
Why?
|
| Molecular Imaging | 1 | 2021 | 48 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2000 | 16 | 0.040 |
Why?
|
| Muscle Neoplasms | 1 | 2000 | 9 | 0.040 |
Why?
|
| Hindlimb | 1 | 2000 | 45 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2000 | 165 | 0.040 |
Why?
|
| Pupil | 1 | 2019 | 9 | 0.040 |
Why?
|
| Infant | 1 | 2005 | 1650 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2000 | 273 | 0.040 |
Why?
|
| Genomics | 1 | 2022 | 370 | 0.040 |
Why?
|
| Algorithms | 1 | 2005 | 1000 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2005 | 1989 | 0.040 |
Why?
|
| Meningeal Neoplasms | 1 | 2019 | 59 | 0.040 |
Why?
|
| Prostate | 1 | 2019 | 90 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 200 | 0.040 |
Why?
|
| Kallikreins | 1 | 2018 | 8 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 377 | 0.040 |
Why?
|
| Equipment Design | 2 | 2014 | 349 | 0.040 |
Why?
|
| Swine | 1 | 2019 | 374 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2017 | 17 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2017 | 23 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 936 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2017 | 67 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2013 | 233 | 0.030 |
Why?
|
| Patient Education as Topic | 2 | 2011 | 474 | 0.030 |
Why?
|
| Pregnancy, Twin | 1 | 2015 | 5 | 0.030 |
Why?
|
| Estramustine | 1 | 2015 | 1 | 0.030 |
Why?
|
| Alleles | 1 | 2017 | 447 | 0.030 |
Why?
|
| Bias | 1 | 1996 | 112 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2015 | 6 | 0.030 |
Why?
|
| Etoposide | 1 | 2015 | 34 | 0.030 |
Why?
|
| Live Birth | 1 | 2015 | 21 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2015 | 99 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 130 | 0.030 |
Why?
|
| Animals | 4 | 2019 | 20619 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2000 | 738 | 0.030 |
Why?
|
| Neurilemmoma | 1 | 1994 | 11 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 1996 | 245 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2014 | 75 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1994 | 488 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2013 | 40 | 0.030 |
Why?
|
| Sarcoma, Experimental | 1 | 1992 | 6 | 0.030 |
Why?
|
| Disease Management | 1 | 2015 | 232 | 0.030 |
Why?
|
| Logistic Models | 1 | 1996 | 1274 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 1992 | 33 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2013 | 42 | 0.020 |
Why?
|
| Health Personnel | 1 | 2017 | 367 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 768 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1992 | 31 | 0.020 |
Why?
|
| Radiology | 1 | 2017 | 252 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 136 | 0.020 |
Why?
|
| Sildenafil Citrate | 1 | 2012 | 14 | 0.020 |
Why?
|
| Mammography | 1 | 2015 | 280 | 0.020 |
Why?
|
| Purines | 1 | 2012 | 42 | 0.020 |
Why?
|
| Thrombocytosis | 1 | 2011 | 3 | 0.020 |
Why?
|
| Radioimmunotherapy | 1 | 2011 | 8 | 0.020 |
Why?
|
| Hyperthyroidism | 1 | 2011 | 19 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 161 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 214 | 0.020 |
Why?
|
| Polycythemia Vera | 1 | 2011 | 7 | 0.020 |
Why?
|
| Ascites | 1 | 2011 | 21 | 0.020 |
Why?
|
| Mice, SCID | 1 | 1992 | 519 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 84 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2011 | 39 | 0.020 |
Why?
|
| Ablation Techniques | 1 | 2011 | 22 | 0.020 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2011 | 7 | 0.020 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2011 | 9 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 281 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 5343 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 53 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 2011 | 74 | 0.020 |
Why?
|
| Documentation | 1 | 2011 | 128 | 0.020 |
Why?
|
| Infection Control | 1 | 2011 | 106 | 0.020 |
Why?
|
| Partial Pressure | 1 | 2010 | 9 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 148 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 125 | 0.020 |
Why?
|
| Physics | 1 | 2010 | 12 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 738 | 0.020 |
Why?
|
| Certification | 1 | 2010 | 54 | 0.020 |
Why?
|
| Accreditation | 1 | 2010 | 77 | 0.020 |
Why?
|
| Pain | 1 | 2011 | 406 | 0.020 |
Why?
|
| Mice | 2 | 2000 | 10816 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 2333 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2010 | 305 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2010 | 864 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 1177 | 0.010 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2004 | 12 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 2674 | 0.010 |
Why?
|
| Bevacizumab | 1 | 2004 | 59 | 0.010 |
Why?
|
| Ischemia | 1 | 2004 | 204 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 212 | 0.010 |
Why?
|
| Lethal Dose 50 | 1 | 1992 | 16 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1992 | 176 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1992 | 387 | 0.010 |
Why?
|
| Cell Survival | 1 | 1992 | 569 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1992 | 2151 | 0.000 |
Why?
|